AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2689470 — intervention group
Group type: COMPARATOR
Intervention: Morphine 5 mg
Number of subjects: 117
Study 2689470 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 117
Study 2689470 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 117
Study 30444691 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser irradiation (n=14)
Number of subjects: 17
Study 30444691 — intervention group
Group type: COMPARATOR
Intervention: Dycal (calcium hydroxide cement; n=14)
Number of subjects: 17
Study 28679020 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg administered with food (evening meal for AF, morning meal for DVT)
Number of subjects: 0
Study 28679020 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg administered with food
Number of subjects: 0
Study 28679020 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg administered with evening meal (AF population)
Number of subjects: 0
Study 28679020 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban 20 mg administered with morning meal (DVT population)
Number of subjects: 0
Study 25034935 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 0.5 mg.kg‐1 (S+K group)
Number of subjects: 80
Study 25034935 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine 1.5 mg.kg‐1 (L5% group)
Number of subjects: 80
Study 25034935 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 15μg (ADR group)
Number of subjects: 80
Study 25034935 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline 3 ml (SF group; control group)
Number of subjects: 80
Study 24151326 — intervention group
Group type: COMPARATOR
Intervention: Standard dose of 25 to 30 minutes of aerobic exercise (STAN)
Number of subjects: 301
Study 24151326 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of 50 to 60 minutes of aerobic exercise (HIGH)
Number of subjects: 301
Study 24151326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dose of 50 to 60 minutes of aerobic and resistance exercise (COMB)
Number of subjects: 301
Study 21218090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (1.2 g)
Number of subjects: 11
Study 21218090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 19388899 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg hyperbaric bupivacaine
Number of subjects: 60
Study 19388899 — intervention group
Group type: COMPARATOR
Intervention: 5 mg hyperbaric bupivacaine with 15 microg of clonidine
Number of subjects: 60
Study 16962532 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Knotless Technique (CKT)
Number of subjects: 214
Study 16962532 — intervention group
Group type: COMPARATOR
Intervention: Interrupted Technique (IT)
Number of subjects: 214
Study 14985138 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.17 l of water every 1/2 hour
Number of subjects: 4
Study 14985138 — intervention group
Group type: COMPARATOR
Intervention: 0.6 l of water every 1/2 hour
Number of subjects: 4
Study 10887323 — intervention group
Group type: EXPERIMENTAL
Intervention: Open food challenges (OFCs) followed by double-blind, placebo-controlled food challenges (DBPCFCs) with Rosaceae foods
Number of subjects: 34
Study 10887323 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests and CAP System (FEIA) with Rosaceae foods
Number of subjects: 34
Study 10887323 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests and CAP System (FEIA)
Number of subjects: 34
Study 10887323 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic challenges including OFC and DBPCFC
Number of subjects: 34
Study 9594556 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release nicotinic acid (KN-SR)
Number of subjects: 136
Study 9594556 — intervention group
Group type: COMPARATOR
Intervention: Ordinary form of nicotinic acid (KN)
Number of subjects: 136
Study 7506174 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (50mg twice daily)
Number of subjects: 40
Study 7506174 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 3450524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 3450524 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated patients)
Number of subjects: 20
Study 31222915 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised teaching and personalized feedback
Number of subjects: 15
Study 30348154 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% beta-cyfluthrin
Number of subjects: 0
Study 30348154 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% beta-cyfluthrin treated inserts
Number of subjects: 0
Study 30348154 — intervention group
Group type: COMPARATOR
Intervention: Fluorescent dust treated inserts
Number of subjects: 0
Study 27043667 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin solution
Number of subjects: 100
Study 27043667 — intervention group
Group type: COMPARATOR
Intervention: 1.5% glucose-based biocompatible neutral pH solution
Number of subjects: 100
Study 24517583 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent strategy to reduce physical restraint use (including development of opinion leaders, education and training of physicians and nurses, implementation of least restraint rounds)
Number of subjects: 0
Study 24517583 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent strategy to reduce physical restraint use
Number of subjects: 0
Study 22449831 — intervention group
Group type: EXPERIMENTAL
Intervention: GB retrieval through umbilical port
Number of subjects: 120
Study 22449831 — intervention group
Group type: COMPARATOR
Intervention: GB retrieval through epigastric port
Number of subjects: 120
Study 19439284 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterine cavity injection of day 2 embryo culture supernatant before day 3 embryo transfer
Number of subjects: 90
Study 19439284 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 90
Study 18308656 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal-bolus insulin regimen (0.5 U/kg total daily dose: 0.25 U/kg insulin glargine and 0.25 U/kg divided into 3 mealtime doses)
Number of subjects: 26
Study 18308656 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (standard care)
Number of subjects: 26
Study 15026400 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic fentanyl hydrochloride (40-microg infusion over 10 minutes)
Number of subjects: 636
Study 15026400 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine (1-mg bolus every 5 minutes; maximum of 10 mg/h)
Number of subjects: 636
Study 15026400 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoretic fentanyl hydrochloride
Number of subjects: 636
Study 15026400 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 636
Study 15026400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 636
Study 11393871 — intervention group
Group type: EXPERIMENTAL
Intervention: Prison-based residential drug treatment
Number of subjects: 2315
Study 9258175 — intervention group
Group type: EXPERIMENTAL
Intervention: GAX 65
Number of subjects: 18
Study 9258175 — intervention group
Group type: COMPARATOR
Intervention: GAX 35
Number of subjects: 18
Study 8485309 — intervention group
Group type: COMPARATOR
Intervention: Fine needle aspiration (FNA) cytology without clinical information
Number of subjects: 80
Study 8485309 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration (FNA) cytology with clinical information
Number of subjects: 80
Study 8485309 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver variability
Number of subjects: 80
Study 3333524 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 14
Study 31261214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain during training
Number of subjects: 0
Study 31261214 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 0
Study 30380535 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 58
Study 30380535 — intervention group
Group type: COMPARATOR
Intervention: Verbal Restructuring (VR)
Number of subjects: 58
Study 30380535 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (WC)
Number of subjects: 58
Study 26941050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette substitute that does not produce an inhalable aerosol
Number of subjects: 520
Study 26941050 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG with 0 mg/ml nicotine concentration
Number of subjects: 520
Study 26941050 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG with 8 mg/ml nicotine concentration
Number of subjects: 520
Study 26941050 — intervention group
Group type: EXPERIMENTAL
Intervention: ECIG with 36 mg/ml nicotine concentration
Number of subjects: 520
Study 26941050 — intervention group
Group type: EXPERIMENTAL
Intervention: All ECIG conditions (0, 8, 36 mg/ml)
Number of subjects: 520
Study 24151956 — intervention group
Group type: COMPARATOR
Intervention: Soccer Group (SG)
Number of subjects: 107
Study 24151956 — intervention group
Group type: COMPARATOR
Intervention: Zumba Group (ZG)
Number of subjects: 107
Study 23205376 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated clinics with actor-patients (24 simulated consultations over four days)
Number of subjects: 128
Study 23205376 — intervention group
Group type: COMPARATOR
Intervention: Community-based attachments with real patients (four days with community-based general practitioners)
Number of subjects: 128
Study 19401423 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated free fatty acids (FFAs)
Number of subjects: 21
Study 19401423 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia
Number of subjects: 21
Study 19401423 — intervention group
Group type: COMPARATOR
Intervention: Rosiglitazone treatment
Number of subjects: 21
Study 17181396 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and calcium (Ex+Ca)
Number of subjects: 88
Study 17181396 — intervention group
Group type: COMPARATOR
Intervention: No effect
Number of subjects: 88
Study 15267039 — intervention group
Group type: EXPERIMENTAL
Intervention: Body diagrams
Number of subjects: 300
Study 15267039 — intervention group
Group type: COMPARATOR
Intervention: No body diagram
Number of subjects: 300
Study 10772502 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aminophylline 500 mg administered 45 minutes prior to SWL
Number of subjects: 10
Study 10772502 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with aminophylline)
Number of subjects: 10
Study 9308788 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (long distance oocyte transport)
Number of subjects: 100
Study 9308788 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (no long distance transport)
Number of subjects: 100
Study 9308788 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1
Number of subjects: 100
Study 9308788 — intervention group
Group type: COMPARATOR
Intervention: Group 2
Number of subjects: 100
Study 8327918 — intervention group
Group type: EXPERIMENTAL
Intervention: Support groups for widows
Number of subjects: 0
Study 8327918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no support groups)
Number of subjects: 0
Study 3537248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine virus at 10(7) TCID50/ml
Number of subjects: 54
Study 3537248 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine virus at 10(8) TCID50/ml
Number of subjects: 54
Study 3537248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 3537248 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccine groups (10(7) and 10(8) TCID50/ml)
Number of subjects: 54
Study 29752170 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) for sleep disordered breathing; mean duration 89 ± 62 days
Number of subjects: 9
Study 27992863 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin plus fenofibrate treatment in patients without CKD
Number of subjects: 5464
Study 27992863 — intervention group
Group type: COMPARATOR
Intervention: Statin plus fenofibrate treatment in patients with CKD
Number of subjects: 5464
Study 25611084 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg BIW
Number of subjects: 287
Study 25611084 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg QW plus topical therapies
Number of subjects: 287
Study 23224792 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once a day, rabeprazole 20 mg twice a day, and tinidazole 500 mg twice daily for 7 days followed by rabeprazole 20 mg OD for 8 weeks
Number of subjects: 131
Study 21206488 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity group (instructed by a physiotherapist to increase physical activity)
Number of subjects: 102
Study 21206488 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructed to maintain lifestyle)
Number of subjects: 102
Study 18495885 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamate antagonists (caroverine and ketamine) administered during sleep
Number of subjects: 0
Study 18495885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16894939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasma urealyticum infection
Number of subjects: 28
Study 16894939 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis infection
Number of subjects: 28
Study 12657228 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBN preservation
Number of subjects: 73
Study 12657228 — intervention group
Group type: COMPARATOR
Intervention: ICBN division
Number of subjects: 73
Study 10709804 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth and death urn with immigration
Number of subjects: 0
Study 10709804 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized version of Polya's urn
Number of subjects: 0
Study 10709804 — intervention group
Group type: COMPARATOR
Intervention: Four adaptive randomization models
Number of subjects: 0
Study 9170519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose MPA (600 mg/day)
Number of subjects: 35
Study 9170519 — intervention group
Group type: COMPARATOR
Intervention: High-dose MPA (1,200 mg/day)
Number of subjects: 35
Study 8253229 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pilocarpine drop medication (2%)
Number of subjects: 30
Study 8253229 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous low-dose pilocarpine delivery by a membrane-controlled Ocusert unit (P40)
Number of subjects: 30
Study 31324831 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5, 10, 20 μg/kg.min)
Number of subjects: 34
Study 31324831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 34
Study 29068453 — intervention group
Group type: EXPERIMENTAL
Intervention: SFA high‐fat meal with orange juice (500 ml)
Number of subjects: 55
Study 29068453 — intervention group
Group type: COMPARATOR
Intervention: SFA high‐fat meal with water (control)
Number of subjects: 55
Study 29068453 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA high‐fat meal with orange juice (500 ml)
Number of subjects: 55
Study 29068453 — intervention group
Group type: COMPARATOR
Intervention: MUFA high‐fat meal with water (control)
Number of subjects: 55
Study 26846284 — intervention group
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Number of subjects: 37
Study 26846284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 24342143 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 2783
Study 24342143 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 2783
Study 24342143 — intervention group
Group type: COMPARATOR
Intervention: Doxazosin
Number of subjects: 2783
Study 22994024 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 2 ml (Group I)
Number of subjects: 105
Study 22994024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (Group II)
Number of subjects: 105
Study 22994024 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg (Group III)
Number of subjects: 105
Study 19838814 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 h skills training plus 30 min of skills testing
Number of subjects: 89
Study 19838814 — intervention group
Group type: COMPARATOR
Intervention: 4 h practice-only control course
Number of subjects: 89
Study 19838814 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing as a final activity in a CPR skills course
Number of subjects: 89
Study 18596740 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 0
Study 18596740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 15768181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive preoperative teaching with two visits using audiovisual aids
Number of subjects: 42
Study 12451077 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop exposure
Number of subjects: 87
Study 12451077 — intervention group
Group type: COMPARATOR
Intervention: Nonexposed physicians
Number of subjects: 87
Study 12451077 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed physicians
Number of subjects: 87
Study 10929726 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized pain therapy with tramadol and diclofenac
Number of subjects: 60
Study 10929726 — intervention group
Group type: COMPARATOR
Intervention: No standardized pain therapy
Number of subjects: 60
Study 8523873 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-treated circuits
Number of subjects: 14
Study 8523873 — intervention group
Group type: COMPARATOR
Intervention: Nontreated circuits
Number of subjects: 14
Study 1742223 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (FA) + 5-fluorouracil (5-FU) (200 mg/sqm i.v. x 5 days + 400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Number of subjects: 182
Study 1742223 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) alone (400 mg/sqm i.v. in 15' x 5 days every 4 weeks)
Number of subjects: 182
Study 6972018 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 96
Study 6972018 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple sulfa cream
Number of subjects: 96
Study 6972018 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 96
Study 6972018 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 96
Study 30448484 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep hypothermic circulatory arrest with retrograde cerebral perfusion (DHCA+RCP)
Number of subjects: 20
Study 30448484 — intervention group
Group type: COMPARATOR
Intervention: Moderate hypothermic circulatory arrest with antegrade cerebral perfusion (MHCA+ACP)
Number of subjects: 20
Study 28731951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 80
Study 28731951 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 80
Study 26304886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide alone (15 mg per day on days 1 to 21, followed by 7 days of rest in cycle 1; then 20 mg per day on days 1 to 21, followed by 7 days of rest in cycles 2 to 12)
Number of subjects: 91
Study 26304886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus Rituximab (LR) (Rituximab 375 mg/m2 weekly for 4 weeks; Lenalidomide as above)
Number of subjects: 91
Study 26304886 — intervention group
Group type: COMPARATOR
Intervention: Control group (Rituximab alone)
Number of subjects: 91
Study 26304886 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 91
Study 24326088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement devices (MADs)
Number of subjects: 19
Study 24326088 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 19
Study 24326088 — intervention group
Group type: EXPERIMENTAL
Intervention: MADs
Number of subjects: 19
Study 21131389 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D cone beam computed tomography (CBCT)
Number of subjects: 27
Study 21131389 — intervention group
Group type: COMPARATOR
Intervention: Conventional two-dimensional (2D) images
Number of subjects: 27
Study 19403229 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP-containing paste
Number of subjects: 15
Study 19403229 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-ACP
Number of subjects: 15
Study 19403229 — intervention group
Group type: EXPERIMENTAL
Intervention: Time below pH 5.7 and time to return to resting pH
Number of subjects: 15
Study 18334764 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 12
Study 18334764 — intervention group
Group type: COMPARATOR
Intervention: Placebo rTMS
Number of subjects: 12
Study 15562056 — intervention group
Group type: EXPERIMENTAL
Intervention: IV lidocaine 1.5 mg/kg
Number of subjects: 502
Study 15562056 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 502
Study 11352682 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum elastin peptides (EP) and procollagen‐IIIN‐terminal propeptide (PIIINP) measured in ng/ml using ELISA and RIA techniques.
Number of subjects: 141
Study 11352682 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive model including EP, PIIINP, and initial AAA size.
Number of subjects: 141
Study 9135021 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with 5-fluorouracil plus levamisole
Number of subjects: 149
Study 9135021 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level c-myc amplification
Number of subjects: 149
Study 9135021 — intervention group
Group type: COMPARATOR
Intervention: c-myc status
Number of subjects: 149
Study 7523647 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified formula (12.8 mg iron per liter)
Number of subjects: 283
Study 7523647 — intervention group
Group type: COMPARATOR
Intervention: Regular formula (1.1 mg iron per liter)
Number of subjects: 283
Study 3061771 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant (ALEC)
Number of subjects: 341
Study 31836609 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib 480 mg b.i.d.
Number of subjects: 28
Study 31836609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31836609 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib 360 mg b.i.d.
Number of subjects: 28